Abrocitinib and Eptifibatide: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 10, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Abrocitinib
Eptifibatide
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
These two medicines can both raise your risk of bleeding, and using them together in your first 3 months on abrocitinib is not recommended. Abrocitinib (Cibinqo) is a pill for eczema that can lower platelets, the tiny cells that help your blood clot. Eptifibatide is a strong IV blood thinner given in the hospital to stop platelets from clumping. Put together, they can make bleeding more likely, such as easy bruising, nosebleeds, or bleeding that is hard to stop.
The good news is that your care team knows about this and can plan around it. Please don't stop either medicine on your own, just talk with your doctor or pharmacist so they can guide you safely.
Interaction: Additive antihemostatic/antiplatelet effect, increasing bleeding risk. Abrocitinib can cause dose-dependent thrombocytopenia; eptifibatide is a GPIIb/IIIa inhibitor that potently blocks platelet aggregation. Neither is a prodrug relevant to this PD interaction; this is pharmacodynamic, not CYP-mediated.
- Direction: increased bleeding risk (additive).
- Severity: contraindicated during the first 3 months of abrocitinib therapy (all antiplatelet agents except low-dose aspirin, 81 mg/day or less).
- Evidence: theoretical; onset unspecified.
- Management: avoid concomitant use in the first 3 months; if antiplatelet therapy is clinically required, defer abrocitinib or select an alternative, and monitor CBC/platelets and bleeding signs.
What happens
Increased risk of bleeding
Interaction Deep Dive
Giving abrocitinib together with antiplatelet drugs is contraindicated throughout the initial 3 months of therapy, with the exception of low-dose aspirin (no more than 81 mg per day), because of a heightened bleeding risk1.
Why it happens (mechanism)
Additive effects on hemostasis
How to manage this interaction
What your care team may do:
- Avoid combining these two, especially during your first 3 months on abrocitinib, since this combination is labeled contraindicated.
- Choose an alternative approach or adjust timing so both aren't given together during that window.
- Watch you more closely for bleeding, including checking blood counts, if the situation ever requires overlapping therapy.
What you should do: Keep taking your medicines as prescribed and do not stop either on your own. Tell your pharmacist and prescriber that you take abrocitinib before any new antiplatelet drug is started, and report unusual bruising, bleeding gums, nosebleeds, or blood in urine or stool right away.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Abrocitinib and Eptifibatide together?
Combining abrocitinib with eptifibatide raises bleeding risk and is contraindicated during the first 3 months of abrocitinib treatment. Do not stop either drug yourself; let your care team coordinate a safe plan. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Abrocitinib and Eptifibatide interaction?
It is rated contraindicated. These should generally not be used together.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Abrocitinib and Eptifibatide interaction managed?
What your care team may do: Avoid combining these two, especially during your first 3 months on abrocitinib, since this combination is labeled contraindicated. Choose an alternative approach or adjust timing so both aren't given together during that window. Watch you more closely for bleeding, including checking blood counts, if the situation ever requires overlapping therapy. What you should do:… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Abrocitinib or Eptifibatide need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: CIBINQO(TM) oral tablets, abrocitinib oral tablets. Pfizer Labs (per FDA), New York, NY, 2022. DailyMed
Keep reading about Abrocitinib
Keep reading about Eptifibatide
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist